中国恶性胸膜间皮瘤临床诊疗指南(2021版)  

Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition)

作　　者：中国医师协会肿瘤多学科诊疗专业委员会 王洁 程颖[3] 高树庚 宋启斌[4] 袁双虎[5] 王志杰 仲佳 谭锋维 Multidisciplinary Committee of Oncology,Chinese Physicians Association;Wang Jie(不详;Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]不详 [2]国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院内科,100021 [3]吉林省肿瘤医院肿瘤内科 [4]武汉大学人民医院肿瘤中心 [5]山东省肿瘤防治研究院胸部肿瘤放疗科

出　　处：《中华肿瘤杂志》2021年第4期383-394,共12页Chinese Journal of Oncology

摘　　要：恶性胸膜间皮瘤(MPM)是来源于胸膜的恶性肿瘤,近年来,发病率逐年上升。因MPM起病隐匿,局部侵袭性强,大多数患者发现时已为晚期。MPM的治疗方式主要包括手术、化疗和放疗。随着免疫治疗的发展,患者的生存得到了进一步改善。为及时反映国内外MPM诊疗的新进展,提高中国MPM的规范化诊疗水平,在现有临床研究证据的基础上,中国医师协会肿瘤多学科诊疗专业委员会结合专家意见,制定了中国MPM临床诊疗指南(2021版)。指南的内容覆盖MPM的流行病学、诊断、病理、治疗及随访等。Malignant pleural mesothelioma(MPM)is a pleura-derived malignant tumor,with a gradually increasing incidence in recent years based on domestic and foreign epidemiologic data.Most patients with MPM are diagnosed at an advanced stage due to its insidiousness and aggressiveness.The therapeutic strategies of MPM mainly include surgery,chemotherapy and radiotherapy.Recently,the immunotherapy has altered the treatment pattern and further improved the survival of these patients.In order to timely present the domestic and foreign progress in the diagnosis and treatment of MPM,and to further improve the level of standardized diagnosis and treatment in MPM in China,this guideline was formulated on the basis of existing clinical research evidence combined with experts′opinions.The guideline covers the epidemiology,diagnosis,pathology,treatment and follow-up of MPM.

关 键 词：恶性胸膜间皮瘤 诊断 治疗 指南 规范 

分 类 号：R734.3[医药卫生—肿瘤]